Challenged by a strict enrollment limit of 1,100 patients, Da Volterra had a sample size re-estimation (SSR) design that only produced marginal gains in power over the fixed sample size.
Facing the risk that a sub-optimal design would prevent a good drug from reaching patients, Da Volterra’s Chief Medical Officer sought a way to consider options that conventional wisdom would ignore.
Working with Cytel’s statistical consultants and their powerful new trial strategy platform Solara, in less than 2 hours Da Volterra was able to examine:
- 151.2 million patient lives simulated
- 1,512 combinations of design options and scenario variants
Find out how Da Volterra was able to use Solara’s revolutionary capabilities to rapidly prioritize design options and confidently select a low-risk trial design within hours.
